Conclusion: This [FDA study reporting on 2,238 subjects] examined the response of patients with keratoconus to an “epi-on” CXL procedure using a novel technique… this represents a safer, noninvasive crosslinking to arrest the progression of keratoconus.
Research Categories
EpiSmart® Crosslinking for Keratoconus: A Phase 2 Study
Authors
Randy J. Epstein, MD; Michael W. Belin, MD; Deborah Gravemann, RN, CCRP; Roxanne Littner, MS; and Roy S. Rubinfeld, MD, MA